Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program

…, Y Yazdanpannah, G Arbess, JG Baril… - Clinical Infectious …, 2013 - academic.oup.com
Many practical clinical questions regarding the management of human immunodeficiency
virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to …

[HTML][HTML] Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced …

JG Baril, JB Angel, MJ Gill, J Gathe, P Cahn… - PLoS …, 2016 - journals.plos.org
Objective We reviewed the current literature regarding antiretroviral (ARV)-sparing therapy
strategies to determine whether these novel regimens can be considered appropriate …

HIV-associated lipodystrophy syndrome: A review of clinical aspects

JG Baril, P Junod, R LeBlanc, H Dion… - Canadian Journal of …, 2005 - hindawi.com
Approximately two years after the introduction of highly active antiretroviral therapy for the
treatment of HIV infection, body shape changes and metabolic abnormalities were …

High rates of forward transmission events after acute/early HIV-1 infection

…, D Moisi, M Ntemgwa, C Matte, JG Baril… - The Journal of …, 2007 - academic.oup.com
Background. A population-based phylogenetic approach was used to characterize human
immunodeficiency virus (HIV)—transmission dynamics in Quebec. Methods. HIV-1 pol …

[HTML][HTML] Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

…, M Klein, A Anis, B Trottier, C Tremblay, JG Baril… - The lancet HIV, 2017 - thelancet.com
Background Data for on-demand pre-exposure prophylaxis (PrEP) are scarce. We implemented
a cohort study to assess its efficacy, safety, and effect on sexual behaviour. Methods We …

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double …

…, E Belonosova, JM Gatell, JG Baril… - The Lancet infectious …, 2013 - thelancet.com
Background In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior
efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for …

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and …

…, B Vandercam, L Vandekerckhove, J Angel, JG Baril… - The Lancet, 2019 - thelancet.com
Background Effective two-drug regimens could decrease long-term drug exposure and toxicity
with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and …

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case–control study using Quebec's public health …

M Durand, O Sheehy, JG Baril, J Lelorier… - JAIDS Journal of …, 2011 - journals.lww.com
Background: Morbidity associated with cardiovascular disease is increasing in the HIV-infected
population. We aimed to study the impact of HIV and of antiretrovirals on acute …

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

M Laverdiere, RG Lalonde, JG Baril… - Journal of …, 2006 - academic.oup.com
Objectives: To illustrate the progressive loss of cross-echinocandin activity on Candida
albicans isolates with strong clonal homology from a patient with advanced HIV infection and …

Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation

C Laprise, A de Pokomandy, JG Baril… - Clinical infectious …, 2013 - academic.oup.com
Background. The current goal of antiretroviral therapy (ART) is to maintain a suppressed human
immunodeficiency virus (HIV) viral load below limits of assay detection. When viral loads …